Cancer Drug Discoveries:
What the future holds (2nd Edition)
| Price: £1,995.00 Approx $2,976.94 (USD) €2,230.91 (EUR) |
|
|---|---|
| Overview: | |
| In 2006, we estimate the global anticancer market was worth over US$47.2 billion (+12% YoY) accounting for 7.3% of global pharmaceutical sales (US$650 billion). Global sales include those of cytotoxics, innovatives (novel therapies, monoclonal antibodies) and antihormonals plus supportive care (drugs given to patients to prevent or treat the toxicities associated with chemotherapy) which accounted for nearly half of global sales. By 2012, the global cancer market is expected to generate sales in excess of US$65 billion due to growth in the sales of existing products and the launch of nearly 60 new products, which will account for around 30% of total drug launches. These will offset the decline in sales of cytotoxics and antihormonals, which face generic sales erosion and the uptake of newer products in preference to these older agents. The cancer treatment market is set to change radically as newer targeted therapies replace broader spectrum treatments. They are generally better tolerated, less toxic and provide better patient outcomes. A trend also to be noted is the rise of combination therapies and earlier drug intervention, often at the surgical stage. Against these positive trends is a growing concern about the rising cost of cancer drugs. With several products now costing US$10,000+, the balance of meeting medical demands against the cost of treatment is an issue in all developed countries. |
|
| Keywords: Breast cancer: Focusing on the changes in the gold standard, the impact of novel therapies on treatment and the new drugs in development. Non-small cell lung cancer: Focusing on the launch of n | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr Cheryl Lee Barton / Publication Date: 21st May 2007